slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 208,891-208,920
Pages 10,126
Rows per page 30
Component
208,891-208,920 of 303,780
07
The slide illustrates a computational workflow for drug formulation optimization.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
08
The slide outlines a three-step computational process: identifying interaction sites, screening a library (SQore), and ranking results.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
10
The slide illustrates a dual-track approach (biophysical studies vs. computational modeling) feeding into an excipient selection matrix.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations Beat · Methodology1 hit
11
Shows CD thermal melt data for Nivolumab, Trastuzumab, Pembrolizumab, and Ustekinumab.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations Beat · Key Takeaways1 hit
12
Data shows percentage of monomer remaining for different stabilizer formulations compared to control.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
13
Data presented as bar charts showing particle counts per ml across different size ranges.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
14
Shows sensorgrams for different concentrations of stabilizers.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
15
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
16
The DLS screen shows hydrodynamic radius (Rh) over time for various buffers; the accelerated stress screen compares 0-week vs 2-week stability across four buffer conditions.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
17
The slide displays three distinct charts: two BLI sensorgrams (top left and bottom left) and one viscosity vs concentration scatter plot (right).Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
19
Includes a scatter plot, bar chart, line chart, and summary table comparing different stabilizer mixtures.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
20
Includes a bar chart of DOE samples, a linear regression plot of pH vs monomer, and a heatmap of sugar vs pH.Comera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
21
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
22
Comera | Investor Presentation Deck | 22 slidesComera | Investor Presentation Deck | 22 slides · Comera Life Sciences
Conference presentation Investor relations 1 hit
02
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a ribbon-style list format to categorize key company information.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The chart uses a horizontal bar format to represent the development stage of various drug candidates.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a grid layout to display headshots, names, titles, and a collection of logos representing past or associated company experience.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide features a compass-like icon, suggesting a navigational or strategic focus for the upcoming section.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
07
The slide illustrates the mechanism of action of a bispecific antibody targeting DLL4 and VEGF-A.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
MTD = Maximum Tolerated Dose; PR = Partial Response; RECIST = Response Evaluation Criteria in Solid Tumors; ORR = Objective Response Rate.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
The chart displays tumor growth percentages for individual patients, categorized by cancer type (Gastric, CRC, Other) and labeled with dosage (mpk).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The table highlights Partial Response (PR) rates with a red border.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The chart highlights a subset of patients with significant tumor reduction (boxed area).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Includes footnotes regarding clinical trial context for hypertension and cytopenia.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The slide presents clinical efficacy data comparing monotherapy vs combination therapy across two metrics.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide illustrates a standard Simon 2-Stage design, a common statistical framework for Phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The table highlights patient age, gender, ECOG status, prior therapies, and cancer subtypes.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
This is a standard oncology 'swimmer's plot' or 'waterfall plot' used to demonstrate clinical efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit